Andere Sprachen Karolinska Development AB London S.E.

Aktien

A0M84G

SE0002190926

0P3C

Markt geschlossen - London S.E. Andere Börsenplätze 16:34:22 06.09.2022			% 5 Tage	% 1. Jan.
2.403 ^SEK	+48.79%		+55.67%	+42.47%

28.05.	Karolinska Development strebt 10%-Beteiligung an Boost Pharma an	MT
16.05.	Karolinska Development AB (Publ) ernennt Hans Wigzell zum Direktor und zum Vorsitzenden	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Karolinska Development : portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator	16.07.
Karolinska Development’s portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator	16.07.
Karolinska Development : portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone	10.07.
Karolinska Development’s portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone	10.07.
Umecrine Cognition AB announced that it has received SEK 28.3 million in funding from Ribbskottet AB, AB Ility AB, Karolinska Development AB and other investors	10.07.
Karolinska Development : portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection	12.06.
Karolinska Development’s portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection	12.06.
Karolinska Development Targets 10% Stake in Boost Pharma	28.05.
Karolinska Development invests in BOOST Pharma, expanding its portfolio	28.05.
Boost Pharma Aps announced that it expects to receive funding from Industrifonden, Karolinska Development AB	28.05.
Karolinska Development : Annual General Meeting 2024	16.05.
Karolinska Development’s Annual General Meeting 2024	16.05.
Karolinska Development AB Appoints Hans Wigzell as Director and as Chairman	16.05.
Karolinska Development’s portfolio company Umecrine Cognition initiates second part of clinical phase 1a/2 study in PBC	08.05.
Interim Report - January-March 2024	26.04.
Karolinska Development AB Reports Earnings Results for the First Quarter Ended March 31, 2024	26.04.
Notice of Annual General Meeting in Karolinska Development AB (publ)	16.04.
Karolinska Development AB Announces That Björn Cochlovius Has Declined Re-Election	16.04.
Karolinska Development : portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	22.03.
Karolinska Development’s portfolio company Umecrine Cognition presents positive safety data from the first part of its Phase 1b/2 study in PBC	22.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Karolinska Development AB London S.E.

Aktien

A0M84G

SE0002190926

0P3C

Andere Sprachen

Filter